<DOC>
	<DOCNO>NCT02216058</DOCNO>
	<brief_summary>A prospective , multicenter study preform evaluate safety efficacy NOYA CoCr biodegradable coat sirolimus-eluting stent treat coronary artery lesion .</brief_summary>
	<brief_title>Safety Efficacy Study NOYA Sirolimus-Eluting Stent Treat Coronary Artery Disease</brief_title>
	<detailed_description>A prospective , multicenter study preform evaluate safety efficacy NOYA CoCr biodegradable coat sirolimus-eluting stent treat coronary artery lesion . Appropriate patient judge inclusion exclusion standard preform stent implantation , patient clinically follow 30 , 180 , 365 days,2 years,3 years,4 year 5 year . Target Lesion Failure ( TLF ) find following-up period key indicator evaluate safety stent . The arrangement , conclusion statistical analysis trial data include clinography angiography fulfil independent Data Management Center ( DMC ) radiography core laboratory .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>The patient must ≥18 age ; male nonpregnant female . Diagnosis coronary artery disease . At least one target lesion diameter stenosis ≥70 % ( visual estimate ) Acceptable candidate CABG ; The patient legally authorize representative inform nature study , agree provision provide write Notice Informed Consent , appropriate Ethics Committee ( EC ) ; patient willing comply specify followup evaluation . Patient congenital heart disease , severe valve dysfunction , bridge vascular disease , severe heart failure ( NYHA ≥ Ⅲ level ) , leave ventricular ejection fraction ≤ 30 % . Patient undergone previous stenting anywhere within previous 1 year . Patient preoperative renal dysfunction : serum creatinine &gt; 2.0mg/dl ( 176.82umol / L ) . Patient history bleed diathesis coagulopathy patient antiplatelet and/or anticoagulant therapy contraindicate patient able comply dual antiplatelet therapy least 1 year ; Patient know hypersensitivity contraindication aspirin , heparin/bivalirudin , clopidogrel/ticlopidine , Prasugrel , stainless steel alloy , cobalt chromium , rapamycin , styrenebutylenestyrene polylactic acid ( PLA ) polymer , and/or contrast sensitivity adequately premedicated ; Patient allergic contrast agent Sirolimus . Patient limit life expectancy le 12 month . Currently participate another investigational drug device study patient inclusion another investigational drug device study followup . Patient poor compliance judgment investigator complete study require . Patient heart transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>